Details for Patent: 12,629,366
Which drugs does patent 12,629,366 protect, and when does it expire?
Patent 12,629,366 protects ARISTADA and is included in one NDA.
This patent has fifty-four patent family members in twenty-three countries.
Summary for Patent: 12,629,366
| Title: | Pharmaceutical compositions comprising sorbitan esters |
| Abstract: | The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs. |
| Inventor(s): | Jason M. PERRY, Daniel R. Deaver, Magali B. HICKEY, Julius F. Remenar, Jennifer VANDIVER |
| Assignee: | Alkermes Pharma Ireland Ltd |
| Application Number: | US18/498,553 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 12,629,366
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-001 | Oct 5, 2015 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF SCHIZOPHRENIA | ⤷ Start Trial | |||
| Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-002 | Oct 5, 2015 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF SCHIZOPHRENIA | ⤷ Start Trial | |||
| Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-003 | Oct 5, 2015 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF SCHIZOPHRENIA | ⤷ Start Trial | |||
| Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-004 | Jun 5, 2017 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF SCHIZOPHRENIA | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,629,366
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2012231160 | ⤷ Start Trial | |||
| Australia | 2017204486 | ⤷ Start Trial | |||
| Australia | 2019202633 | ⤷ Start Trial | |||
| Australia | 2020250309 | ⤷ Start Trial | |||
| Brazil | 112013023847 | ⤷ Start Trial | |||
| Canada | 2830511 | ⤷ Start Trial | |||
| China | 103561746 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
